Jeff Thiel

Jeff joined JenaValve Technology, Inc. in 2019, bringing over 30 years of experience in medical device technologies.

Jeff started his medical device career with St. Jude Medical where he led the transition of mechanical heart valve production from St. Paul to Puerto Rico. He has also held leadership roles as the President and CEO of Radiance Medical Systems (RADX) which developed a novel radiation balloon for the treatment of in-stent restenosis. In addition, Jeff also served on the Board of Directors at Micrus Endovascular which transitioned from a start-up to a publicly traded company eventually acquired by Johnson & Johnson.

Prior to joining Jenavalve, Jeff was the President and CEO of Devax, Inc., a drug eluting stent company which received CE Mark and US IDE approval for it’s Axxess bifurcation stent.

Jeff earned his MBA from the Opus College of Business at the University of St. Thomas and a BS in Economics from the University of Wisconsin-River Falls.